TY  - JOUR

T1  - Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease

JO  - JAMA Cardiology

UR  - http://eprints.whiterose.ac.uk/147798/

PY  - 2019/06/05

AU  - Fonarow GC

AU  - van Hout B

AU  - Villa G

AU  - Arellano J

AU  - Lindgren P

ED  - 

DO  - DOI: 10.1001/jamacardio.2019.1647

PB  - American Medical Association

Y2  - 2024/12/22

ER  -